Travere Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$1.36 | -$0.70 | -$0.96 |
| Q2 2024 | 6 | -$1.12 | -$0.58 | -$0.79 |
| Q3 2024 | 3 | -$0.95 | -$0.49 | -$0.67 |
| Q4 2024 | 9 | -$0.81 | -$0.46 | -$0.63 |
| Q1 2025 | 6 | -$0.70 | -$0.12 | -$0.45 |
| Q2 2025 | 5 | -$0.38 | -$0.20 | -$0.27 |
| Q3 2025 | 5 | -$0.29 | -$0.15 | -$0.20 |
| Q4 2025 | 5 | $0.05 | $0.10 | $0.07 |
Travere Therapeutics, Inc. Earnings Date And Information
Travere Therapeutics, Inc. last posted its earnings results on Thursday, October 31st, 2024. The company reported $-0.7 earnings per share for the quarter, missing analysts' consensus estimates of $-0.7 by $0. The company had revenue of 62.90 M for the quarter and had revenue of 145.24 M for the year. Travere Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-1.5 diluted earnings per share) and currently has a price-to-earnings ratio of -4.01. Travere Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based on prior year's report dates.
Travere Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/31/2024 | Q3 2024 | -$0.70 | -$0.70 | 0 | $60.87 M | $62.90 M |
| 08/01/2024 | Q2 2024 | -$0.87 | -$0.91 | -0.04 | $50.40 M | $54.12 M |
| 05/06/2024 | Q1 2024 | -$0.98 | -$1.76 | -0.78 | $41.37 M | |
| 02/20/2024 | Q4 2023 | -$1.18 | $45.06 M | |||
| 11/07/2023 | Q3 2023 | -$1.09 | -$0.99 | 0.1 | $57.33 M | $37.10 M |
| 08/03/2023 | Q2 2023 | -$1.16 | -$1.13 | 0.03 | $53.56 M | $59.70 M |
| 05/04/2023 | Q1 2023 | -$1.18 | -$1.27 | -0.09 | $56.99 M | |
| 02/23/2023 | Q4 2022 | -$1.04 | -$1.03 | 0.01 | $55.87 M | |
| 10/27/2022 | Q3 2022 | -$0.97 | -$1.09 | -0.12 | $54.12 M | $53.50 M |
| 08/04/2022 | Q2 2022 | -$0.94 | -$1.05 | -0.11 | $49.63 M | $54.17 M |
| 05/05/2022 | Q1 2022 | -$0.85 | -$1.20 | -0.35 | $48.49 M | |
| 02/24/2022 | Q4 2021 | -$0.72 | -$0.84 | -0.12 | $57.25 M | |
| 10/28/2021 | Q3 2021 | -$0.59 | $60.93 M | $68.22 M | ||
| 07/29/2021 | Q2 2021 | -$0.73 | -$0.64 | 0.09 | $50.33 M | $54.62 M |
| 05/06/2021 | Q1 2021 | -$0.56 | -$0.96 | -0.4 | $47.41 M | |
| 03/01/2021 | Q4 2020 | -$0.43 | -$2.37 | -1.94 | $50.98 M | |
| 11/05/2020 | Q3 2020 | -$0.52 | -$0.44 | 0.08 | $47.84 M | $51.14 M |
| 07/30/2020 | Q2 2020 | -$0.58 | $47.59 M | $48.43 M | ||
| 05/11/2020 | Q1 2020 | -$0.67 | $0.02 | 0.69 | $47.77 M | |
| 02/24/2020 | Q4 2019 | -$0.64 | -$0.70 | -0.06 | $46.69 M |
Travere Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Travere Therapeutics, Inc.'s earnings date?
Travere Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates.
-
How can I listen to Travere Therapeutics, Inc.'s earnings conference call?
The conference call for Travere Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Travere Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Travere Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Travere Therapeutics, Inc. generate each year?
Travere Therapeutics, Inc. (:TVTX) has a recorded annual revenue of $145.24 M.
-
How much profit does Travere Therapeutics, Inc. generate each year?
Travere Therapeutics, Inc. (:TVTX) has a recorded net income of $145.24 M. Travere Therapeutics, Inc. has generated $-1.5 earnings per share over the last four quarters.
-
What is Travere Therapeutics, Inc.'s price-to-earnings ratio?
Travere Therapeutics, Inc. (:TVTX) has a price-to-earnings ratio of -4.01 and price/earnings-to-growth ratio is -0.67.
